These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36897520)

  • 1. A Prospective, Observational Study Assessing Effectiveness, Safety, and QoL of Greek Patients with Multiple Sclerosis Under Treatment with Fingolimod.
    Mitsikostas DD; Orologas A; Dardiotis E; Fakas N; Doskas T; Karageorgiou K; Maltezou M; Iliopoulos I; Vikelis M; Grigoriadis N
    Adv Ther; 2023 May; 40(5):2217-2233. PubMed ID: 36897520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East.
    Achiron A; Aref H; Inshasi J; Harb M; Alroughani R; Bijarnia M; Cooke K; Yuksel O
    BMC Neurol; 2017 Aug; 17(1):150. PubMed ID: 28784108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
    Tichá V; Počíková Z; Vytlačil J; Štěpánová R
    BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Outcomes in Fingolimod-Treated Patients with Multiple Sclerosis in the Czech Republic: Results from the 12-Month GOLEMS Study.
    Tichá V; Kodým R; Počíková Z; Kadlecová P
    Clin Drug Investig; 2017 Feb; 37(2):175-186. PubMed ID: 27785735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U;
    J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world retrospective study of effectiveness and safety of FINgOlimod in relapsing remitting multiple sclerosis in the Middle East and North Africa (FINOMENA).
    Alroughani R; AlKawi Z; Hassan A; Al Otaibi H; Mujtaba A; Al Atat R; Riachi N; Akkawi N; Koussa S; Inshasi J; Alsaadi T; Ahmed SF; Al-Aasmi A; Zakaria M; El Fadally H
    Clin Neurol Neurosurg; 2021 Apr; 203():106576. PubMed ID: 33714799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of fingolimod: Real-world data from a long-term, non-interventional study on the treatment of RRMS patients spanning up to 5 years from Hungary.
    Biernacki T; Sandi D; Füvesi J; Fricska-Nagy Z; Kincses TZ; Ács P; Rózsa C; Dobos E; Cseh B; Horváth L; Nagy Z; Csányi A; Kovács K; Csépány T; Vécsei L; Bencsik K;
    PLoS One; 2022; 17(4):e0267346. PubMed ID: 35452476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany.
    Ziemssen T; Lang M; Tackenberg B; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Couto CA; Findlay JA; Cornelissen C;
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e548. PubMed ID: 30882022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
    Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
    Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
    Izquierdo G; Damas F; Páramo MD; Ruiz-Peña JL; Navarro G
    PLoS One; 2017; 12(4):e0176174. PubMed ID: 28453541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study.
    Barrero F; Mallada-Frechin J; Martínez-Ginés ML; Marzo ME; Meca-Lallana V; Izquierdo G; Ara JR; Oreja-Guevara C; Meca-Lallana J; Forero L; Sánchez-Vera I; Moreno MJ;
    PLoS One; 2020; 15(4):e0230846. PubMed ID: 32240213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran.
    Ouspid E; Razazian N; Moghadasi AN; Moradian N; Afshari D; Bostani A; Sariaslani P; Ansarian A
    Neurosciences (Riyadh); 2018 Apr; 23(2):129-134. PubMed ID: 29664454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan.
    Yang CC; Ro LS; Tsai NW; Lin CC; Huang WN; Tsai CP; Lin TS; Su JJ; Huang CC; Lyu RK; Chen HH; Lee WJ; Chen PL; Yang A
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):542-550. PubMed ID: 32669233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
    PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effectiveness of fingolimod in a Portuguese real-world population.
    Correia I; Batista S; Marques IB; Sousa M; Ferreira R; Nunes C; Macário MC; Sousa L
    Mult Scler Relat Disord; 2016 Mar; 6():41-48. PubMed ID: 27063621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.
    Hestvik ALK; Frederiksen JL; Nielsen HH; Torkildsen Ø; Eek C; Huang-Link Y; Haghighi S; Tsai JA; Kant M
    Mult Scler Relat Disord; 2022 Jul; 63():103892. PubMed ID: 35696880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.
    Fox E; Edwards K; Burch G; Wynn DR; LaGanke C; Crayton H; Hunter SF; Huffman C; Kim E; Pestreich L; McCague K; Barbato L;
    Mult Scler Relat Disord; 2014 Sep; 3(5):607-19. PubMed ID: 26265273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Term Effectiveness of Fingolimod for Multiple Sclerosis in a Real-World Clinical Setting.
    Uzunköprü C; Beckmann Y; Türe S
    Eur Neurol; 2021; 84(3):200-205. PubMed ID: 33827097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to fingolimod in PREFERMS: Effect of treatment history and naïvety on clinical, MRI and treatment satisfaction outcomes
    Hunter SF; Thomas FP; Cascione M; Williams IM; Meng X; Schofield L; Weiss JL; Tenenbaum N; Cree BAC;
    Mult Scler Relat Disord; 2020 Oct; 45():102346. PubMed ID: 32717684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study.
    Ordoñez-Boschetti L; Rey R; Cruz A; Sinha A; Reynolds T; Frider N; Alvarenga R
    Adv Ther; 2015 Jul; 32(7):626-35. PubMed ID: 26170105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.